NCT06676072已完成不适用
Safety and Effectiveness of the TactiFlex SE Catheter and Volt Pulsed Field Ablation (PFA) Generator in Subjects With Paroxysmal Atrial Fibrillation
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 188
- 试验地点
- 32
- 主要终点
- Proportion of subjects experiencing a device and/or procedure-related serious adverse event with onset within 7 days of any ablation procedure (index or repeat procedure performed 0-90 days post initial procedure).
研究概览
简要总结
The objective of this clinical study is to demonstrate that ablation with the TactiFlex SE Ablation catheter, in conjunction with a compatible pulsed field ablation (PFA) and/or radio frequency (RF) generator, is safe and effective for the treatment of symptomatic, recurrent, drug refractory paroxysmal atrial fibrillation (PAF).
详细描述
This is a pre-market, prospective, single-arm, non-randomized, multicenter clinical study to demonstrate safety and effectiveness for the treatment of symptomatic, recurrent, drug-refractory PAF.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Documented symptomatic paroxysmal atrial fibrillation (PAF). Documentation requirements are as follows:
- •Physician's note indicating recurrent self-terminating AF with ≥ 2 episodes of PAF within the 6 months prior to enrollment AND
- •One electrocardiographically documented PAF episode within 12 months prior to enrollment.
- •NOTE: Documented evidence of the AF episode must either be continuous AF on a 12-lead ECG or include at least 30 seconds of continuous AF from another ECG device.
- •Plans to undergo a catheter ablation procedure due to symptomatic PAF and is refractory, intolerant, or contraindicated to at least one Class I-IV AAD medication
- •At least 18 years of age
- •Able and willing to comply with all trial requirements including pre- procedure, post-procedure, and follow-up testing and requirements
- •Informed of the nature of the trial, agreed to its provisions, and has provided written informed consent as approved by the Institutional Review Board/Ethics Committee (IRB/EC) of the respective clinical trial site.
排除标准
- •Previously diagnosed persistent or long-standing persistent atrial fibrillation (Continuous AF greater than 1 year in duration)
- •Arrhythmia due to reversible causes including thyroid disorders, acute alcohol intoxication, electrolyte imbalance, severe untreated sleep apnea, and other major surgical procedures in the preceding 90 days
- •Known presence of cardiac thrombus
- •Left atrial diameter (LAD) > or equal to 5.0 cm (anteroposterior diameter) within 180 days prior to the index procedure
- •Left ventricular ejection fraction (LVEF) < or equal to 35% as assessed with echocardiography or computerized tomography (CT) within 180 days prior to the index procedure
- •New York Heart Association (NYHA) class III or IV heart failure
- •Body mass index > or equal to 40 kg/m2
- •Pregnant or nursing
- •Patients who have had a ventriculotomy or atriotomy within the preceding 28 days of procedure
- •Myocardial infarction (MI), acute coronary syndrome, percutaneous coronary intervention (PCI), or valve or coronary bypass grafting surgery within preceding 90 days
- •Stroke or TIA (transient ischemic attack) within the last 90 days
- •Heart disease in which corrective surgery is anticipated within 180 days after procedure
- •History of blood clotting or bleeding abnormalities including thrombocytosis, thrombocytopenia, bleeding diathesis, or suspected anti- coagulant state
- •Contraindication to long-term anti-thromboembolic therapy
- •Patient unable to receive heparin or an acceptable alternative to achieve adequate anticoagulation
- •Known sensitivity to contrast media (if needed during the procedure) that cannot be controlled with pre-medication
- •Previous left atrial surgical or left atrial catheter ablation procedure (including left atrial appendage (LAA) closure device)
- •Plans to have an LAA closure device implanted during the follow-up period
- •Presence of any condition that precludes appropriate vascular access
- •Severe mitral regurgitation (regurgitant volume ≥ 60 mL/beat, regurgitant fraction ≥ 50%, and/or effective regurgitant orifice area ≥ 0.40cm2)
- •Previous tricuspid or mitral valve replacement or repair
- •Patients with prosthetic valves
- •Patients with a myxoma
- •Patients with an interatrial baffle or patch as the transseptal puncture could persist and produce an iatrogenic atrial shunt
- •Stent, constriction, or stenosis in a pulmonary vein
- •Rheumatic heart disease
- •Hypertrophic cardiomyopathy
- •Active systemic infection
- •Renal failure requiring dialysis
- •Severe pulmonary disease (e.g., restrictive pulmonary disease, constrictive or chronic obstructive pulmonary disease) or any other disease or malfunction of the lungs or respiratory system that produces severe chronic symptoms
- •Presence of an implantable therapeutic cardiac device including permanent pacemaker, biventricular pacemaker, or any type of implantable cardiac defibrillator (with or without biventricular pacing function) or planned implant of such a device for any time during the follow-up period. Presence of an implantable loop recorder is acceptable as long as it is removed prior to insertion of the investigational device.
- •Patient is currently participating in another clinical trial or has participated in a clinical trial within 30 days prior to screening that may interfere with this clinical trial without pre-approval from this study Sponsor
- •Unlikely to survive the protocol follow up period of 12 months
- •Presence of other medical, anatomic, comorbid, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results.
- •Individuals without legal authority
- •Individuals unable to read or write
研究组 & 干预措施
TactiFlex Ablation catheter
Experimental
A single use catheter that is designed to facilitate electrophysiological mapping of the heart chambers and to transmit RF current or PFA therapy to the catheter's flexible tip electrode for intracardiac ablation purposes.
干预措施: PFA Ablation catheter (Device)
结局指标
主要结局
Proportion of subjects experiencing a device and/or procedure-related serious adverse event with onset within 7 days of any ablation procedure (index or repeat procedure performed 0-90 days post initial procedure).
时间窗: 7 days
Freedom from documented (symptomatic or asymptomatic) AF/AFL/AT episodes of greater than 30 seconds duration that are documented by protocol-specified 12-lead ECG, TTM or Holter monitor (HM) devices after the index ablation procedure
时间窗: 12 months
次要结局
- Symptomatic Effectiveness(12 months)
- AAD-Free Effectiveness(12 months)
研究者
研究点 (32)
Loading locations...
相似试验
撤回
不适用
Safety and Effectiveness of TactiFlex* Ablation Catheter, Sensor Enabled* (TactiFlex SE) for the Treatment of Drug Refractory, Symptomatic, Paroxysmal Atrial Fibrillation (TactiFlex PAF IDE Trial)NL-OMON49407St. Jude Medical60
已完成
不适用
ExAblate UF V2 System for the Treatment of Symptomatic Uterine FibroidsUterine FibroidsNCT01285960InSightec108
已完成
不适用
Safety and Effectiveness of TactiCath™ Contact Force, Sensor Enabled™ (TactiCath SE) Catheter for Ablation of Drug Refractory, Symptomatic, Persistent Atrial FibrillationPersistent Atrial FibrillationNCT03650556Abbott Medical Devices224
已完成
2 期
Clinical Evaluation of Therapy™ Cool Flex Ablation Catheter for the Treatment of Paroxysmal Atrial FibrillationParoxysmal Atrial FibrillationNCT01185613Abbott Medical Devices50
已完成
不适用
TactiSense IDE Trial of TactiCath SE for Paroxysmal Atrial FibrillationParoxysmal Atrial FibrillationNCT03354663Abbott Medical Devices156